Hypoxic Stem Cell Culture Supernatant for Solid Tumor Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapeutic agents, often become ineffective due to drug resistance and have significant side effects, while immunotherapy has limited capability in controlling solid tumors without causing substantial harm.
Innovation Solution
A pharmaceutical composition is developed using a culture supernatant from immortalized dental pulp stem cells, specifically grown under hypoxic conditions, which contains elevated levels of growth factors like IGF-1 and VEGF, to control macrophage populations around solid tumors, thereby inhibiting cancer cell growth or killing tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used for cancer treatment, then tumor growth inhibition is achieved, but drug resistance develops and side effects occur
Solution Approach 1:
The patent uses culture supernatant from dental pulp stem cells as an intermediary substance to treat cancer. The supernatant contains growth factors and cytokines that modulate the tumor microenvironment, particularly affecting macrophage polarization toward an anti-tumor phenotype, thereby inhibiting tumor growth without the direct cytotoxicity of conventional chemotherapeutic agents, thus avoiding drug resistance and severe side effects
Solution Approach 2:
The patent changes the oxygen concentration parameter during stem cell culture (using hypoxic conditions of 1-5% O2) to optimize the production of anti-tumor factors in the culture supernatant. This parameter change enhances the therapeutic efficacy of the supernatant while maintaining its selective toxicity toward tumor cells, thereby improving tumor growth inhibition without increasing harmful side effects
2Object-affected harmful factors
If immunotherapy is used for cancer treatment, then side effects are reduced, but capability to control solid tumors is limited
Solution Approach 1:
The culture supernatant acts as an intermediary that bridges immunotherapy and tumor control by modulating macrophage function. The supernatant contains cytokines and growth factors that reprogram tumor-associated macrophages from pro-tumor to anti-tumor phenotypes, thereby enhancing tumor control capability while maintaining the low side effect profile characteristic of immunotherapy
Solution Approach 2:
The patent optimizes the immunomodulatory activity of the culture supernatant by controlling oxygen concentration during stem cell culture. Hypoxic conditions enhance the production of specific cytokines that are more effective at polarizing macrophages toward anti-tumor phenotypes, thereby improving tumor control capability while preserving the favorable side effect profile
Data Source
Figure 1
Figure 2(A)~2(D)
Figure 3(A)~3(F)
AI summary
The purpose of the present invention is to provide a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27°C under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.